🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NIVO plus IPI vs CTx or NIVO for MSI-H/dMMR mCRC: #ASCO25 🔎Expanded analyses from CheckMate 8HW 👉ORR N/I vs N71 vs 58% 👉mPFS N/I vs CTx nr vs 30.8 mo 👉mPFS N/I vs N 54 vs 5.9 mo 🧐 Highly effective treatment, acceptable toxicity, supports N/I as SOC ESMO - Eur. Oncology

More evidence that ADCs are active in the CNS. This should be the end of automatic exclusions of patients with active brain mets from ADC trials.

ctDNA-guided adj CTx escalation in stage III CRC #ASCO25 🔎Primary analysis of the ctDNA-positive cohort from the randomized AGITG DYNAMIC-III trial 👉mRFS 29 vs 36 mo 👉CTx escalation does not improve outcome 🧐 ctDNA very helpful to understand risk groups, but we need better

#ASCO25 started with very interesting data on #NET Jaume Capdevila from Vall d’Hebron Institute of Oncology (VHIO) on #obrixtamig in #epNEC BITE-Phase I Manageable safety (CRS) Higher ORR and longer DOR if highDLL3 DAREON-5 trial ongoing in highDLL3 Combos with chemo for lowDLL3? Grupo GETNE ASCO NET- ESPAÑA

#ASCO25 👀 at some of these responses! 👇🏽These are patients with MSS🧊(“cold tumors”), not the MSI-High🔥(“hot tumors”). This is a big unmet need in colorectal cancer and other cancers. 🔗 meetings.asco.org/abstracts-pres… Vilastobart (XTX101) Tumor-activated CTLA4⛔️ ➕PDL1- OncoAlert

Nick Turner presents OS results from INAVO120. Adding inavo to 1L fulv/palvo for high-risk PIK3CAm HR+/HER2- MBC improved PFS (17 vs 7 m) & OS (34 vs 27 mo), though low crossover to alpelisib (10%). Toxicities non-negligible. Concomitant NEJM publication: nejm.org/doi/full/10.10…

🔥Plenary Discussion of LBA1🔥 #ASCO2025 👏Excellent disucssion by Myriam Chalabi 👉May neoadjuvant be more effective? 👉Do we need chemotherapy? ESMO - Eur. Oncology

📢 #ASCO25 | DB-1311/BNT324 B7H3 ADC in Heavily Pretreated CRPC: Phase I/II in CRPC (n=65) shows ORR 27.9%, DCR 95.3%; median rPFS 8.3 m; manageable safety (G≥3 TRAEs 40%). by Andrew Parsonson et al. Full abstract → [shorturl.at/meFe4] ASCO The ASCO Post Journal of Clinical Oncology

👏 we need funding-Federal level & state/territory supported . Call for action COSA Medical Oncology Group of Australia (MOGA) Anthony Albanese - it’s not just cardiac & pulmonary rehab that should be funded . Why is Cancer Cancer Australia the poor cousin in this ? An EPC gets diluted by other allied health .

Dr Andrew Parsonson Macquarie University Dhanusha Sabanathan Alison Zhang Great work by Dr Andrew Parsonson and the phase 1 team at MQ University Clinical Trials Unit Macquarie University . This agent is highly active in metastatic prostate cancer and heading towards phase 3

Thanks Zach Klaassen for covering our #ASCO25 presentation on DB-1311 / BNT324 (a novel #B7H3 #ADC) in patients with heavily pretreated CRPC for UroToday.com 🔗 Link: bit.ly/3ZdPN7C Recruitment ongoing MQ University Clinical Trials Unit Howard Gurney John Park Dhanusha Sabanathan Alison Zhang

It was a pleasure to sit down with Joaquin Mateo from Vall d’Hebron Institute of Oncology (VHIO) & Capu B from Gustave Roussy for ecancer to discuss emerging #Phase1 therapies such as #ADCs and T-cell engagers 🔗 New MOAs in prostate cancer treatment - what’s next? - ecancer ecancer.org/en/video/12402… MQ University Clinical Trials Unit